123 related articles for article (PubMed ID: 32603443)
1. Developing Quality Programs for Cell-Free DNA (cfDNA) Extraction from Peripheral Blood.
Samoila A; Sosa J; Padilla J; Wutkowski M; Vanness K; Viale A; Berger M; Houck-Loomis B; Pessin M; Peerschke EI
J Appl Lab Med; 2020 Jul; 5(4):788-797. PubMed ID: 32603443
[TBL] [Abstract][Full Text] [Related]
2. A Study of Pre-Analytical Variables and Optimization of Extraction Method for Circulating Tumor DNA Measurements by Digital Droplet PCR.
Cavallone L; Aldamry M; Lafleur J; Lan C; Gonzalez Ginestet P; Alirezaie N; Ferrario C; Aguilar-Mahecha A; Basik M
Cancer Epidemiol Biomarkers Prev; 2019 May; 28(5):909-916. PubMed ID: 30824523
[TBL] [Abstract][Full Text] [Related]
3. The Effect of Preservative and Temperature on the Analysis of Circulating Tumor DNA.
Parpart-Li S; Bartlett B; Popoli M; Adleff V; Tucker L; Steinberg R; Georgiadis A; Phallen J; Brahmer J; Azad N; Browner I; Laheru D; Velculescu VE; Sausen M; Diaz LA
Clin Cancer Res; 2017 May; 23(10):2471-2477. PubMed ID: 27827317
[No Abstract] [Full Text] [Related]
4. Preanalytical blood sample workup for cell-free DNA analysis using Droplet Digital PCR for future molecular cancer diagnostics.
van Ginkel JH; van den Broek DA; van Kuik J; Linders D; de Weger R; Willems SM; Huibers MMH
Cancer Med; 2017 Oct; 6(10):2297-2307. PubMed ID: 28940814
[TBL] [Abstract][Full Text] [Related]
5. IQN path ASBL report from the first European cfDNA consensus meeting: expert opinion on the minimal requirements for clinical ctDNA testing.
Deans ZC; Butler R; Cheetham M; Dequeker EMC; Fairley JA; Fenizia F; Hall JA; Keppens C; Normanno N; Schuuring E; Patton SJ
Virchows Arch; 2019 Jun; 474(6):681-689. PubMed ID: 31028539
[TBL] [Abstract][Full Text] [Related]
6. Preanalytical variables that affect the outcome of cell-free DNA measurements.
Ungerer V; Bronkhorst AJ; Holdenrieder S
Crit Rev Clin Lab Sci; 2020 Nov; 57(7):484-507. PubMed ID: 32393081
[TBL] [Abstract][Full Text] [Related]
7. Circulating Cell-Free Tumor DNA Analysis of 50 Genes by Next-Generation Sequencing in the Prospective MOSCATO Trial.
Jovelet C; Ileana E; Le Deley MC; Motté N; Rosellini S; Romero A; Lefebvre C; Pedrero M; Pata-Merci N; Droin N; Deloger M; Massard C; Hollebecque A; Ferté C; Boichard A; Postel-Vinay S; Ngo-Camus M; De Baere T; Vielh P; Scoazec JY; Vassal G; Eggermont A; André F; Soria JC; Lacroix L
Clin Cancer Res; 2016 Jun; 22(12):2960-8. PubMed ID: 26758560
[TBL] [Abstract][Full Text] [Related]
8. Blood Collection and Cell-Free DNA Isolation Methods Influence the Sensitivity of Liquid Biopsy Analysis for Colorectal Cancer Detection.
Barták BK; Kalmár A; Galamb O; Wichmann B; Nagy ZB; Tulassay Z; Dank M; Igaz P; Molnár B
Pathol Oncol Res; 2019 Jul; 25(3):915-923. PubMed ID: 29374860
[TBL] [Abstract][Full Text] [Related]
9. Optimization of Preanalytical Variables for cfDNA Processing and Detection of ctDNA in Archival Plasma Samples.
Nesic M; Bødker JS; Terp SK; Dybkær K
Biomed Res Int; 2021; 2021():5585148. PubMed ID: 34307658
[TBL] [Abstract][Full Text] [Related]
10. Application of circulating tumor DNA in prospective clinical oncology trials - standardization of preanalytical conditions.
van Dessel LF; Beije N; Helmijr JC; Vitale SR; Kraan J; Look MP; de Wit R; Sleijfer S; Jansen MP; Martens JW; Lolkema MP
Mol Oncol; 2017 Mar; 11(3):295-304. PubMed ID: 28164427
[TBL] [Abstract][Full Text] [Related]
11. External Quality Assurance of Current Technology for the Testing of Cancer-Associated Circulating Free DNA Variants.
Chai SY; Peng R; Zhang R; Zhou L; Pillay N; Tay KH; Badrick T; Li J; Horan MP
Pathol Oncol Res; 2020 Jul; 26(3):1595-1603. PubMed ID: 31487000
[TBL] [Abstract][Full Text] [Related]
12. Statistical analysis of mutant allele frequency level of circulating cell-free DNA and blood cells in healthy individuals.
Xia L; Li Z; Zhou B; Tian G; Zeng L; Dai H; Li X; Liu C; Lu S; Xu F; Tu X; Deng F; Xie Y; Huang W; He J
Sci Rep; 2017 Aug; 7(1):7526. PubMed ID: 28790338
[TBL] [Abstract][Full Text] [Related]
13. High-throughput isolation of circulating tumor DNA: a comparison of automated platforms.
van Dessel LF; Vitale SR; Helmijr JCA; Wilting SM; van der Vlugt-Daane M; Oomen-de Hoop E; Sleijfer S; Martens JWM; Jansen MPHM; Lolkema MP
Mol Oncol; 2019 Feb; 13(2):392-402. PubMed ID: 30516338
[TBL] [Abstract][Full Text] [Related]
14. Collection of cell-free DNA for genomic analysis of solid tumors in a clinical laboratory setting.
Raymond CK; Hernandez J; Karr R; Hill K; Li M
PLoS One; 2017; 12(4):e0176241. PubMed ID: 28448587
[TBL] [Abstract][Full Text] [Related]
15. The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients.
Zill OA; Banks KC; Fairclough SR; Mortimer SA; Vowles JV; Mokhtari R; Gandara DR; Mack PC; Odegaard JI; Nagy RJ; Baca AM; Eltoukhy H; Chudova DI; Lanman RB; Talasaz A
Clin Cancer Res; 2018 Aug; 24(15):3528-3538. PubMed ID: 29776953
[No Abstract] [Full Text] [Related]
16. Performance of Streck cfDNA Blood Collection Tubes for Liquid Biopsy Testing.
Medina Diaz I; Nocon A; Mehnert DH; Fredebohm J; Diehl F; Holtrup F
PLoS One; 2016; 11(11):e0166354. PubMed ID: 27832189
[TBL] [Abstract][Full Text] [Related]
17. A novel strategy for highly efficient isolation and analysis of circulating tumor-specific cell-free DNA from lung cancer patients using a reusable conducting polymer nanostructure.
Lee H; Jeon S; Seo JS; Goh SH; Han JY; Cho Y
Biomaterials; 2016 Sep; 101():251-7. PubMed ID: 27294542
[TBL] [Abstract][Full Text] [Related]
18. Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced Cancer.
Janku F; Zhang S; Waters J; Liu L; Huang HJ; Subbiah V; Hong DS; Karp DD; Fu S; Cai X; Ramzanali NM; Madwani K; Cabrilo G; Andrews DL; Zhao Y; Javle M; Kopetz ES; Luthra R; Kim HJ; Gnerre S; Satya RV; Chuang HY; Kruglyak KM; Toung J; Zhao C; Shen R; Heymach JV; Meric-Bernstam F; Mills GB; Fan JB; Salathia NS
Clin Cancer Res; 2017 Sep; 23(18):5648-5656. PubMed ID: 28536309
[No Abstract] [Full Text] [Related]
19. High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants.
Razavi P; Li BT; Brown DN; Jung B; Hubbell E; Shen R; Abida W; Juluru K; De Bruijn I; Hou C; Venn O; Lim R; Anand A; Maddala T; Gnerre S; Vijaya Satya R; Liu Q; Shen L; Eattock N; Yue J; Blocker AW; Lee M; Sehnert A; Xu H; Hall MP; Santiago-Zayas A; Novotny WF; Isbell JM; Rusch VW; Plitas G; Heerdt AS; Ladanyi M; Hyman DM; Jones DR; Morrow M; Riely GJ; Scher HI; Rudin CM; Robson ME; Diaz LA; Solit DB; Aravanis AM; Reis-Filho JS
Nat Med; 2019 Dec; 25(12):1928-1937. PubMed ID: 31768066
[TBL] [Abstract][Full Text] [Related]
20. Assessing HER2 Amplification in Plasma cfDNA.
Garcia-Murillas I; Turner NC
Methods Mol Biol; 2018; 1768():161-172. PubMed ID: 29717443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
